Plasma, Intestine and Tumor Levels of 5-Fluorouracil in Mice Bearing L1210 Ascites Tumor Following Oral Administration of 5-Fluorouracil, UFT (Mixed Compound of Tegafur and Uracil), Carmofur and 5'-Deoxy-5-fluorouridine.
- 1 January 2001
- journal article
- research article
- Published by Pharmaceutical Society of Japan in Biological & Pharmaceutical Bulletin
- Vol. 24 (11), 1329-1331
- https://doi.org/10.1248/bpb.24.1329
Abstract
Several 5-fluorouracil (5-FU) derivatives, 1-hexylcarbamoyl-5-fluorouracil (HCFU), 5'-deoxy-5-fluorouridine (5'-DFUR) and UFT (mixed compound of tegafur and uracil), have been developed and clinically widely used. However, comparative pharmacokinetic studies of the parent compound and other fluorinated drivatives have not been precisely reported. The dosage of the oral clinical use for human cancer of 5-FU, HCFU, 5'-DFUR and UFT as tegafur (FT) is 200-300mg/d, 600mg/d, 800-1,200mg/d and 300-600mg/d respectively. These amounts of the drugs are almost equimolar. Previously, we reported the effect of oral equimolar administration of each four drugs on thymidilate synthase activity, deoxyribonucleotide metabolism and cell cycle progression in L1210 ascites tumor. (1,2) In this study, we examined the antitumor effect and 5-FU concentration in the plasma, intestine and tumor after oral equimolar administrations of each drug using BDF1 mice bearing L1210 ascites tumor. In our study, UFT showed the best life prolongation among these four drugs. The intestine 5-FU level was highest by treatment with 5-FU during the initial 4 h. The plasma 5-FU level was highest by treatment with HCFU for 4 h. But the tumor 5-FU level was highest by treatment with UFT over the 24 h. In spite of the high plasma 5-FU concentration after the treatment with HCFU, the 5-FU concentration in the tumor was below the detectable level until 24 h. These findings suggested that the highest specific accumulation of 5-FU in tumor cells may explain the best therapeutic results of UFT.Keywords
This publication has 10 references indexed in Scilit:
- Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastasesCancer, 2000
- Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer.Journal of Clinical Oncology, 1998
- Uracil-tegafur in gastric carcinoma: a comprehensive review.Journal of Clinical Oncology, 1998
- Correlation between augmentative effects of leucovorin on 5-fluorouracil and thymidylate synthase inhibitionInternational Journal of Clinical Oncology, 1997
- Effects of UFT (Mixed Compound of Tegafur and Uracil) on Cell Kinetics and Inhibition of Thymidylate Synthase in L1210 Ascites TumorCancer Investigation, 1995
- A phase II study of combination therapy with 5′-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary fociCancer, 1993
- Effects of 5-Fluorouracil and a Combination of Tegafur and Uracil (UFT) on Nucleotide Metabolism in L1210 Ascites TumorCancer Investigation, 1993
- Pharmacokinetic Modulation of Plasma 5-Fluorouracil Concentrations to Potentiate the Antitumor Activity of Continuous Venous Infusion of 5-FluorouracilJapanese Journal of Cancer Research, 1989
- Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosidesJournal of Medicinal Chemistry, 1979
- THE SYNTHESIS OF 5-FLUOROPYRIMIDINESJournal of the American Chemical Society, 1957